ReviewReported positiveLimited evidenceTier 4 · clinical
Drugs · Jun 2026 · regulatory approval summary
Relacorilantepithelial ovarian cancerfallopian tube cancerprimary peritoneal cancerpancreatic cancerprostate cancer Relacorilant is a non-steroidal, selective glucocorticoid receptor antagonist being developed for several solid tumours and Cushing syndrome. The article reports that relacorilant received its first approval in the USA on 25 March 2026 for use in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after 1-3 prior systemic regimens (at least one including bevacizumab). The article summarizes development milestones leading to this approval.
Studied with: nab-paclitaxel.
Key findings
- Relacorilant is a non-steroidal, selective glucocorticoid receptor II antagonist developed by Corcept Therapeutics.
- Relacorilant received first approval in the USA on 25 March 2026.
- Approval is for use in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens, at least one of which included bevacizumab.
- Relacorilant is being developed for various solid tumours including ovarian, fallopian tube, peritoneal, pancreatic and prostate cancers, as well as for Cushing syndrome.
- The article summarizes milestones in the development of relacorilant leading to this approval.
Limitations: Abstract provides no efficacy or safety outcome data or numeric results from trials.; No trial design, sample size, or methods are reported in the abstract.; This is an approval/summary article, not primary trial data.; Geographic scope limited to a USA approval; supporting evidence is not detailed in the abstract..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewReported positiveModerate evidenceTier 4 · clinical
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · Sep 2025 · narrative review
ovarian cancerfallopian tube cancerperitoneal cancerepithelial ovarian cancersovarian germ cell malignanciesovarian stromal malignancies
This is a narrative review updating FIGO staging and summarizing current knowledge on ovarian, fallopian tube, and peritoneal cancers. It describes the 2014 FIGO staging revisions (including subdivisions of Stage IC and IIIC/IIIA) and summarizes genetics, surgical management, chemotherapy, targeted therapies, and aspects of germ cell and stromal ovarian malignancies. The review notes that high-grade serous carcinoma is the most common histology and that no feasible screening strategies currently exist.
Key findings
- FIGO's 2014 staging revision groups ovarian, fallopian tube, and peritoneal cancers in the same system and subdivides Stage IC into IC1 (surgical spill), IC2 (preoperative capsule rupture or tumor on surface), and IC3 (malignant cells in ascites or peritoneal washings).
- Stage IIIC was revised to include a category for spread to retroperitoneal lymph nodes without intraperitoneal dissemination, subdivided into IIIA1(i) (metastasis ≤10 mm) and IIIA1(ii) (metastasis >10 mm); Stage IIIA2 is now defined as microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph nodes.
- Most of these malignancies are high-grade serous carcinomas (HGSCs).
- There are currently no feasible screening strategies for ovarian cancer.
- Diagnosis, treatment, surveillance, and survival have improved due to advances in radiology, pathology, genomics, and molecular biology, and individualized care emphasizes precision surgery to limit morbidity.
- Germline genetic analysis and identification of somatic mutations in tumor tissue provide data informing the use of targeted agents and immunotherapy; the review also covers chemotherapy and management of germ cell and stromal ovarian malignancies.
Limitations: Narrative review with no original patient-level data presented; Abstract does not report review methods, search strategy, or criteria for evidence selection (not identified as a systematic review or meta-analysis); No new primary quantitative data or pooled estimates provided in this abstract.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human trialTrialReported positiveStrong evidenceTier 4 · clinicaln = 381
Lancet (London, England) · Jun 2025 · randomized, controlled, open-label phase 3 trial
Relacorilantplatinum-resistant ovarian cancerepithelial ovarian cancerprimary peritoneal cancerfallopian tube cancer This phase 3 randomized trial tested whether adding relacorilant to nab-paclitaxel helped women with platinum-resistant ovarian cancer. The combination improved progression-free survival and also showed a longer overall survival at an interim analysis. Side effects were similar between groups after accounting for nab-paclitaxel exposure, and no new safety signals were seen.
Reported effects: progression-free survival hazard ratio 0.7 [0.54–0.91], p p=0.0076, n=381 · progression-free survival median 6.54 mo [5.55–7.43], n=188 · +3 more
Studied with: nab-paclitaxel.
Key findings
- Progression-free survival was significantly longer with relacorilant plus nab-paclitaxel than with nab-paclitaxel alone.
- An interim overall survival analysis also favored the combination.
- Adverse events were similar across groups when adjusted for nab-paclitaxel exposure; no new safety signals were observed.
Limitations: Open-label design; Overall survival result was based on a planned interim analysis; Trial is ongoing; Funding from the drug manufacturer.
This study evaluated relacorilant as an added anticancer agent in platinum-resistant ovarian cancer.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Case reportInconclusiveLimited evidenceTier 3 · early humann = 1
International journal of surgery case reports · Oct 2024 · case report
fallopian tube cancerhigh-grade serous adenocarcinoma
This is a case report of a 68-year-old woman whose first manifestation of primary fallopian tube high-grade serous adenocarcinoma was painless bilateral inguinal lymph node enlargement. Imaging and biopsy suggested an adnexal malignancy; surgery found a right fallopian tube tumor with minimal intraperitoneal spread. The patient underwent cytoreductive surgery followed by six cycles of paclitaxel plus cisplatin and later entered a clinical trial. The authors highlight that isolated inguinal node metastasis from tubal cancer is rare and recommend detailed evaluation and close follow-up in similar cases.
Reported effects: right inguinal mass size, n=1 · left inguinal mass size, n=1 · +6 more
Key findings
- Patient presented with painless bilateral inguinal enlargement (7 × 6 cm on the right side, 3 × 2 cm on the left side) and preoperative biopsy showed metastatic high-grade serous adenocarcinoma.
- Imaging (MRI/CT/PET-CT) showed an adnexal lesion with maximum cross-section about 7.5 × 7.0 × 4.0 cm and hypermetabolic lymph nodes including bilateral inguinal nodes.
- Serum tumor markers were markedly elevated: CA125 922.40 U/ml and HE4 394.50 pmol/L.
- At exploratory laparotomy a solid tumor about 10 × 6 × 6 cm was found confined to the right rear of the uterus with almost no pelvic-abdominal spread but 50 ml of pale blood-colored peritoneal fluid.
- Patient underwent cytoreductive surgery, received six cycles of paclitaxel plus cisplatin (three 3-week intervals), and subsequently participated in a clinical trial.
Limitations: Single case report (n=1) limits generalizability.; No control group or comparative data.; Abstract does not report long-term outcomes or follow-up duration.; No mechanistic or experimental proof of proposed lymphatic/hematogenous spread pathways—suggestive only..
AI summary of the abstract, human-reviewed · Aug 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewMixed resultsModerate evidenceTier 4 · clinical
Journal of the National Comprehensive Cancer Network : JNCCN · Oct 2024 · Practice guideline / guideline insights
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
These NCCN Guidelines Insights summarize multidisciplinary diagnostic workup, staging, and treatment recommendations for ovarian, fallopian tube, and primary peritoneal cancers. The report specifically describes how the evolving use of PARP inhibitors as maintenance and single-agent regimens informed the panel's recommendations.
Key findings
- NCCN Guidelines provide multidisciplinary diagnostic workup, staging, and treatment recommendations for ovarian, fallopian tube, and primary peritoneal cancers.
- The Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens informed panel recommendations in the guidelines.
Limitations: Abstract is a guideline summary and does not present original trial data or numerical results.; No specific recommendations, dosing, comparative efficacy, or level-of-evidence details are provided in the abstract.; Limited methodological detail in abstract about how evidence was reviewed or how recommendations were updated..
Guideline update addressing clinical management of ovarian/fallopian tube/primary peritoneal cancers with attention to PARP inhibitor use.
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed